A first-in-human study of ANN-001 for treatment of alpha-1 antitrypsin (A1AT) deficiency

Trial Profile

A first-in-human study of ANN-001 for treatment of alpha-1 antitrypsin (A1AT) deficiency

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs ADVM 043 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Mar 2017 According to an Adverum Biotechnologies media release, company plans to initiate patient enrollment during the fourth quarter of 2017.
    • 13 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top